Navigation Links
InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
Date:8/20/2012

TEL AVIV, Israel, August 20, 2012 /PRNewswire/ --

InspireMD, Inc. (OTCBB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary MGuard™ embolic protection stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that a multi-center randomized trial of its MGuard™ embolic protection stent demonstrated a positive outcome in treating patients suffering heart attacks when compared to commercially-approved bare metal or drug-eluting stents.

Detailed results will be presented at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in Miami (October 22-26, 2012).

"We have reached a key milestone in the history of InspireMD," said Ofir Paz, the Company's chief executive officer. "We look forward to presenting detailed results of the MGuard™ MASTER trial at the TCT in October."  

The MASTER (MGuard forAcute ST Elevation Reperfusion) trial enrolled 433 patients in nine countries and was designed to evaluate the MGuard™ embolic protection stent compared to commercially-approved bare metal or drug-eluting stents in heart attack patients undergoing primary percutaneous coronary intervention (PCI).

Heart attacks are the leading cause of death in the industrialized world.  Approximately 3.2 million stenting procedures are expected to be performed worldwide in 2012, of which 850,000, or about 26 percent, will be for patients having heart attacks.  Stents for heart attack patients are expected to represent $1.8 billion of stent sales, or nearly 30 percent of the $5.9 billion global stent market.

The MGuard™ embolic protection stent is a coronary stent integrated with a proprietary micronet technology.  The micronet is designed to hold plaque and thrombus in place against the blocked art
'/>"/>

SOURCE Inspire MD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD to Present at Harvard Investors Group on June 27 in New York
2. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
3. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
4. InspireMD Announces First Quarter 2012 Financial Results
5. Angeion Announces Name Change and New Trading Symbol Effective Tuesday, August 21, 2012
6. VWR Funding, Inc. Announces Proposed Offering Of Senior Notes
7. VWR Funding, Inc. Announces Tender Offer Of Existing PIK Toggle Notes
8. Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
9. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
10. ShangPharma Announces Second Quarter 2012 Results
11. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... 30, 2014  According to their CEO, ... clinical trials is going through a complete transformation ... work of the current clinical trial management process ... generation, clinical trials, which will ultimately drive the ... The company has been recognized by the National ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... presented results from a global Phase II study of ... of cerebral beta-Amyloid plaques, at the 19th World Congress ... the Phase II study was to investigate the efficacy ... diagnosis of probable Alzheimer,s disease and Healthy Volunteers (HVs). ...
... MTD ) today announced third quarter results for 2009. ... currency declined by 12% in the quarter. Reported sales decreased ... Net earnings per diluted share as reported (EPS) were $1.21, ... EPS was $1.36, a 6% decline from the prior-year amount of ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:10/1/2014)... scientists has shown that more than 80 per cent ... , The study found that medicines called ,JAK inhibitors, ... mutation that is present in more than 80 per ... used, or are in clinical trials, for diseases including ... Bowel cancer is the second-most common cancer in Australia ...
(Date:10/1/2014)... a policy focus on expanding access to care ... continues to have significant dental disease. In this ... American Dental Association , researchers from Tufts University ... Dental Medicine report on the first large-scale survey ... by caregivers to adults with developmental disabilities. The ...
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... 01, 2014 Innovations announces the upcoming ... broadcast on Monday, October 20, 2014 at 7:30 a.m. ... will go behind the scenes to learn about Break ... will explore the practical help and information Break the ... the warning signs of abuse, how to navigate the ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... , SAN DIEGO, Nov. 13 "The greatest ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091110/AQ08403 ) , In dealing with life,s challenges, ... to a happier, more abundant life. Apparel industry veteran Scott ... dear friend who had suffered a tragic loss and he didn,t ...
... researchers say , FRIDAY, Nov. 13 (HealthDay News) -- A ... enough to determine if he or she acts aggressively, a ... current issue of the journal Psychological Science suggests ... specifically the ratio of the distance between the right and ...
... plays a role, but a lesser one than age, study finds ... seven times higher in 70-year-old women than in 50-year-old women, according ... fracture rises sharply with age. , The analysis of data from ... and older also found that among women aged 50 to 54, ...
... Ill., Nov. 13 CCH has issued a special ... in the House version of health care reform, detailing ... access the new Briefing, visit http://hr.cch.com/pdf/SpecialReport_HealthcareReform_11-09.pdf ... America Act made its way through the House of ...
... , SAN JOSE, Calif., Nov. 13 Human Pheromone Sciences, ... announced results for the three and nine month periods ended ... 2009, net revenues of $273,000 represented a 4% increase from ... resulted in net income of $10,000 ($0.00 per share) as ...
... to correct repeated federal violations prompts agency action , ... Justice, on behalf of the U.S. Food and Drug Administration, ... Haifa Smoked Fish Inc. of Jamaica, N.Y., and two of ... and Cosmetic Act. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...
Cached Medicine News:Health News:HeartThreads(TM) -- New Line of Inspirational Tee Shirts Designed to Motivate and Foster Overall Mental Health & Wellness Available at HeartThreadsClothing.com 2Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 2Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 3Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 4Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 5Health News:Human Pheromone Sciences Announces Third Quarter Results 2Health News:Human Pheromone Sciences Announces Third Quarter Results 3Health News:Human Pheromone Sciences Announces Third Quarter Results 4Health News:FDA Takes Action Against Seafood Processing Company, Executives 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: